ESMO2012肺癌集锦课件.ppt

GOOD SIENCEBETTER MEDICINE BEST PRACTICE ESMO Highlights Part A Milan, Italy 8-12 October 2010 IASLC-ETOP European Multidisciplinary Workshop Robert Pirker (Austria) Federico Cappuzzo (Italy) Martin Filipits (Austria) Dominique Grunenwald (France) Felix Herth (Germany) Keith Kerr (UK) Helmut Popper (Austria) Rafael Rosell (Spain) Egbert Smit (Netherlands) Rolf Stahel (Switzerland) 123 participants 18 countries Multidisciplinary Biologists Pathologists Chest physicians Medical oncologists Surgeons Others Steering committee Participants Pirker et al. ELCC 2010; Abstract 201O * * EGFR mutation testing; European workshop group recommendations – main results/comments IASLC-ETOP multidisciplinary workshop in order to facilitate implementation of EGFR mutation testing in Europe Recommendations: Close collaboration/coordination among specialists, essential Decision to request EGFR mutation testing to be made bytreating physicians All NSCLC pts should eventually be tested Several methods can be used Tumor specimen and DNA extraction: handling and fixation important; quality of DNA crucial Results to be available within 7 working days This effort will help to implement standardized EGFR mutation testing in clinical practice and therefore facilitate customized treatment in NSCLC Pirker et al. ELCC 2010; Abstract 201O * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ESMO Highlights 2010 Lung Cancer A randomized phase III study comparing gefitinib with carboplatin/ paclitaxel for the first-line treatment of non-small cell lung cancer with sensitive EGFR mutations: NEJ002 study Akira Inoue et al On behalf of the North-East Japan Study Group, Tohoku University Hospital, Sendai, Japan Inoue et al. ECCO-ESMO 2009; Abstract 9LBA Study design Primary endpoint: Progression-free survival (PFS) Secondary endpoints: Overall survival, overall response rate, toxicity profiles, quality of life, time to PS 3 (data not shown) NSCLC with sensitive EGFR mutations